血清可溶性CD14水平升高表明多发性硬化症病情稳定。
Increased serum levels of soluble CD14 indicate stable multiple sclerosis.
作者信息
Lutterotti Andreas, Kuenz Bettina, Gredler Viktoria, Khalil Michael, Ehling Rainer, Gneiss Claudia, Egg Robert, Deisenhammer Florian, Berger Thomas, Reindl Markus
机构信息
Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria.
出版信息
J Neuroimmunol. 2006 Dec;181(1-2):145-9. doi: 10.1016/j.jneuroim.2006.09.002. Epub 2006 Oct 13.
The aim of this study was to evaluate a possible role of soluble CD14 (sCD14) in multiple sclerosis (MS). We found that sCD14 serum levels measured by ELISA were higher in MS patients compared to neurological and healthy controls. Within the MS group sCD14 levels were increased in relapsing-remitting and secondary progressive MS compared to primary progressive MS. Furthermore, sCD14 concentrations were increased during stable disease. An increased expression of sCD14 was also detected after treatment with interferon-beta. In summary, we report evidence that serum sCD14 levels are increased in MS and correlate inversely with disease activity in relapsing MS patients.
本研究的目的是评估可溶性CD14（sCD14）在多发性硬化症（MS）中的可能作用。我们发现，通过酶联免疫吸附测定（ELISA）检测，MS患者血清中的sCD14水平高于神经疾病患者和健康对照。在MS组中，复发缓解型和继发进展型MS患者的sCD14水平高于原发进展型MS患者。此外，在病情稳定期sCD14浓度升高。用β-干扰素治疗后也检测到sCD14表达增加。总之，我们报告的证据表明，MS患者血清sCD14水平升高，且与复发型MS患者的疾病活动呈负相关。
Zotero 插件